Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBased on limited metadata, this FDA Warning Letter issued to Asclemed USA Inc., operating as Enovachem, concerns drug product manufacturing or distribution operations. While the specific violations cannot be detailed without access to the full letter text, the warning indicates regulatory concerns identified during FDA oversight of the company's drug-related activities. The letter was issued by the FDA's drug regulatory division in June 2019, though the specific issuing office and detailed violation count are not available in the provided metadata.